KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Total Liabilities (2016 - 2025)

Historic Total Liabilities for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $343.4 million.

  • CRISPR Therapeutics AG's Total Liabilities rose 1080.03% to $343.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $343.4 million, marking a year-over-year increase of 1080.03%. This contributed to the annual value of $343.4 million for FY2025, which is 1080.03% up from last year.
  • CRISPR Therapeutics AG's Total Liabilities amounted to $343.4 million in Q4 2025, which was up 1080.03% from $329.3 million recorded in Q3 2025.
  • CRISPR Therapeutics AG's Total Liabilities' 5-year high stood at $399.4 million during Q3 2022, with a 5-year trough of $152.4 million in Q1 2021.
  • Moreover, its 5-year median value for Total Liabilities was $349.6 million (2021), whereas its average is $337.8 million.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Total Liabilities soared by 13702.79% in 2022 and then tumbled by 1185.51% in 2024.
  • Over the past 5 years, CRISPR Therapeutics AG's Total Liabilities (Quarter) stood at $352.4 million in 2021, then rose by 4.3% to $367.6 million in 2022, then decreased by 5.66% to $346.8 million in 2023, then decreased by 10.62% to $310.0 million in 2024, then increased by 10.8% to $343.4 million in 2025.
  • Its last three reported values are $343.4 million in Q4 2025, $329.3 million for Q3 2025, and $318.6 million during Q2 2025.